HIV-1 infections with multiple founders associate with the development of neutralization breadth.

Autor: Eric Lewitus, Samantha M Townsley, Yifan Li, Gina C Donofrio, Bethany L Dearlove, Hongjun Bai, Eric Sanders-Buell, Anne Marie O'Sullivan, Meera Bose, Hannah Kibuuka, Lucas Maganga, Sorachai Nitayaphan, Fredrick K Sawe, Leigh Anne Eller, Nelson L Michael, Victoria R Polonis, Julie A Ake, Sandhya Vasan, Merlin L Robb, Sodsai Tovanabutra, Shelly J Krebs, Morgane Rolland

Publikováno v: PLoS Pathogens, Vol 18, Iss 3, p e1010369 (2022)

Eliciting broadly neutralizing antibodies (bnAbs) is a cornerstone of HIV-1 vaccine strategies. Comparing HIV-1 envelope (env) sequences from the first weeks of infection to the breadth of antibody responses observed several years after infection can

Externí odkaz: https://doaj.org/article/113e99203ef947cfad3ab559159eb9c8

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Autor: Craig A. Magaret, Li Li, Allan C. deCamp, Morgane Rolland, Michal Juraska, Brian D. Williamson, James Ludwig, Cindy Molitor, David Benkeser, Alex Luedtke, Brian Simpkins, Fei Heng, Yanqing Sun, Lindsay N. Carpp, Hongjun Bai, Bethany L. Dearlove, Elena E. Giorgi, Mandy Jongeneelen, Boerries Brandenburg, Matthew McCallum, John E. Bowen, David Veesler, Jerald Sadoff, Glenda E. Gray, Sanne Roels, An Vandebosch, Daniel J. Stieh, Mathieu Le Gars, Johan Vingerhoets, Beatriz Grinsztejn, Paul A. Goepfert, Leonardo Paiva de Sousa, Mayara Secco Torres Silva, Martin Casapia, Marcelo H. Losso, Susan J. Little, Aditya Gaur, Linda-Gail Bekker, Nigel Garrett, Carla Truyers, Ilse Van Dromme, Edith Swann, Mary A. Marovich, Dean Follmann, Kathleen M. Neuzil, Lawrence Corey, Alexander L. Greninger, Pavitra Roychoudhury, Ollivier Hyrien, Peter B. Gilbert

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-22 (2024)

Abstract In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 v

Externí odkaz: https://doaj.org/article/ae82624b40e944a5925f8f3c70ded9b7

Defining the risk of SARS-CoV-2 variants on immune protection

Autor: Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, Florian Krammer, Alba Grifoni, Arghavan Alisoltani, Galit Alter, Rama R. Amara, Ralph S. Baric, Dan H. Barouch, Jesse D. Bloom, Louis-Marie Bloyet, Gaston Bonenfant, Adrianus C. M. Boon, Eli A. Boritz, Debbie L. Bratt, Traci L. Bricker, Liliana Brown, William J. Buchser, Juan Manuel Carreño, Liel Cohen-Lavi, Tamarand L. Darling, Meredith E. Davis-Gardner, Bethany L. Dearlove, Han Di, Meike Dittmann, Nicole A. Doria-Rose, Daniel C. Douek, Christian Drosten, Venkata-Viswanadh Edara, Ali Ellebedy, Thomas P. Fabrizio, Guido Ferrari, Will M. Fischer, William C. Florence, Ron A. M. Fouchier, John Franks, Adolfo García-Sastre, Adam Godzik, Ana Silvia Gonzalez-Reiche, Aubree Gordon, Bart L. Haagmans, Peter J. Halfmann, David D. Ho, Michael R. Holbrook, Yaoxing Huang, Sarah L. James, Lukasz Jaroszewski, Trushar Jeevan, Robert M. Johnson, Terry C. Jones, Astha Joshi, Yoshihiro Kawaoka, Lisa Kercher, Marion P. G. Koopmans, Bette Korber, Eilay Koren, Richard A. Koup, Eric B. LeGresley, Jacob E. Lemieux, Mariel J. Liebeskind, Zhuoming Liu, Brandi Livingston, James P. Logue, Yang Luo, Adrian B. McDermott, Margaret J. McElrath, Victoria A. Meliopoulos, Vineet D. Menachery, David C. Montefiori, Barbara Mühlemann, Vincent J. Munster, Jenny E. Munt, Manoj S. Nair, Antonia Netzl, Anna M. Niewiadomska, Sijy O’Dell, Andrew Pekosz, Stanley Perlman, Marjorie C. Pontelli, Barry Rockx, Morgane Rolland, Paul W. Rothlauf, Sinai Sacharen, Richard H. Scheuermann, Stephen D. Schmidt, Michael Schotsaert, Stacey Schultz-Cherry, Robert A. Seder, Mayya Sedova, Alessandro Sette, Reed S. Shabman, Xiaoying Shen, Pei-Yong Shi, Maulik Shukla, Viviana Simon, Spencer Stumpf, Nancy J. Sullivan, Larissa B. Thackray, James Theiler, Paul G. Thomas, Sanja Trifkovic, Sina Türeli, Samuel A. Turner, Maria A. Vakaki, Harm van Bakel, Laura A. VanBlargan, Leah R. Vincent, Zachary S. Wallace, Li Wang, Maple Wang, Pengfei Wang, Wei Wang, Scott C. Weaver, Richard J. Webby, Carol D. Weiss, David E. Wentworth, Stuart M. Weston, Sean P. J. Whelan, Bradley M. Whitener, Samuel H. Wilks, Xuping Xie, Baoling Ying, Hyejin Yoon, Bin Zhou, Tomer Hertz, Derek J. Smith, Michael S. Diamond, Diane J. Post, Mehul S. Suthar

Publikováno v: Nature

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced following infection or vaccination. To address the public health threat caused by the increasing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e896e07b5a30bbcb962870bf7aaa91b
https://www.repository.cam.ac.uk/handle/1810/335637

A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants

Autor: Nelson L. Michael, Hongjun Bai, Bethany L. Dearlove, Sandhya Vasan, Mihret F. Amare, Eric Lewitus, Kayvon Modjarrad, Daniel B. Reeves, Morgane Rolland, Paul T. Scott, M. Gordon Joyce, Yifan Li

Publikováno v: Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences of the United States of America

The magnitude of the COVID-19 pandemic underscores the urgency for a safe and effective vaccine. Many vaccine candidates focus on the Spike protein, as it is targeted by neutralizing antibodies and plays a key role in viral entry. Here we investigate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a324c28282fb07c95b04be903ccf6e

A SARS-CoV-2 vaccine candidate would likely match all currently circulating strains

Autor: Bethany L. Dearlove, Paul T. Scott, Mihret F. Amare, Sandhya Vasan, Eric Lewitus, Hongjun Bai, Daniel B. Reeves, Yifan Li, Kayvon Modjarrad, Nelson L. Michael, M. Gordon Joyce, Morgane Rolland

The magnitude of the COVID-19 pandemic underscores the urgency for a safe and effective vaccine. Here we analyzed SARS-CoV-2 sequence diversity across 5,700 sequences sampled since December 2019. The Spike protein, which is the target immunogen of mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81962d3f3ea972fd1635008d2a337bc0
https://doi.org/10.1101/2020.04.27.064774